Senator Joe Manchin, a moderate Democrat considered a crucial vote within the party’s slim Senate majority, said Janet Woodcock, the temporary head of the Food and Drug Administration, should be quickly replaced with a permanent leader.
Manchin blasted an FDA decision to approve the controversial Alzheimer’s therapy Aduhelm despite conflicting evidence that the Biogen Inc. drug works and an overwhelmingly negative vote against the therapy by agency advisers. The FDA ruling led three members of that panel to quit in protest… [Read more…] about US Senator Joe Manchin calls for a new FDA Commissioner to replace current (acting) one who “has repeatedly ignored public health concerns and shown a dereliction of duty” over opioids and aducanumab
Wellcome are delighted to announce the launch of our Workplace Mental Health 2021 Request for Proposals.
Businesses all over the world are increasingly thinking about how they can most effectively support the mental health of their staff, even more so in light of the Covid-19 pandemic. However, despite growing interest and investment in workplace mental health, we still have so much to learn about what works. [Read more…] about Ten days left to submit proposals to the Wellcome Trust for Workplace Mental Health 2021
Like many people, I was shocked when the Food and Drug Administration ignored the advice of its neurological drugs advisory panel and broadly approved Biogen’s new drug, Aduhelm, even for populations never included in the clinical trials to assess the drug. [Read more…] about First, do no harm? Six reasons to approach anti-amyloid drug Aduhelm cautiously, if at all
ICER Issues Statement on the FDA’s Approval of Aducanumab for Alzheimer’s Disease (Institute for Clinical and Economic Review):
The Institute for Clinical and Economic Review (ICER) believes that the FDA, in approving aducanumab (Aduhelm™, Biogen) for the treatment of Alzheimer’s disease, has failed in its responsibility to protect patients and families from unproven treatments with known harms. [Read more…] about Growing backlash against the FDA approval of unproven Alzheimer’s treatment Aduhelm, by Biogen
People who retire early suffer from accelerated cognitive decline and may even encounter early onset of dementia, according to a new economic study (Note: opens PDF) I conducted with my doctoral student Alan Adelman.
To establish that finding, we examined the effects of a rural pension program China introduced in 2009 that provided people who participated with a stable income if they stopped working after the official retirement age of 60. We found that people who participated in the program and retired within one or two years experienced a cognitive decline equivalent to a drop in general intelligence of 1.7% relative to the general population. This drop is equivalent to about three IQ points and could make it harder for someone to adhere to a medication schedule or conduct financial planning. The largest negative effect was in what is called “delayed recall,” which measures a person’s ability to remember something mentioned several minutes ago. Neurological research links problems in this area to an early onset of dementia. [Read more…] about Study in China finds that retirement may accelerate cognitive decline, even for those with stable income
Rice University Charges Into the Future with Magnetics and Bioimplants (All About Circuits):
Advances in self-generating drug delivery systems, brain-to-brain communication, and injury mitigation technologies are just some of the newest research coming down the pipeline from Rice University.
Several research projects funded by the Defense Advanced Research Project Agency’s (DARPA) N3 program might herald a future of highly advanced human-machine interfacing that expands the capabilities of soldiers and first responders. [Read more…] about DARPA-funded nonsurgical neurotechnologies push the frontier of brain-machine interfaces